Back to search results

Sonobiopsy for Glioblastoma Detection

This study is looking at a new way to detect glioblastoma (a type of brain cancer) using a method called Sonobiopsy. Sonobiopsy uses ultrasound combined with tiny bubbles (microbubbles) to help collect tumor markers from your blood. Researchers will compare these blood samples taken before and after Sonobiopsy to your tumor tissue to see how well it works. The goal is to see if Sonobiopsy can help doctors understand the cancer's genetic makeup better, which could lead to more personalized treatment. You may be able to join if you are an adult with a newly diagnosed glioblastoma that meets certain size and location requirements on an MRI scan. The study aims to enroll 40 participants, but its current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 40 participants. It is not specified if it is randomized, blinded, or what phase it is in.
What's involved
You would have blood drawn at several time points around the Sonobiopsy procedure. This includes before, and then 10, 30 (optional), and 60 (optional) minutes after the ultrasound.
Compensation
Not stated in the trial record.
Follow-up
The primary goals of the study are measured on Day 1, focusing on changes in tumor DNA levels and matched mutations.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05281731

Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

Recruiting
NAAges 18+InterventionalDiagnostic
Washington University School of Medicine
~40 participants
Updated 2026-05-14 on ClinicalTrials.gov
What's tested:SonobiopsyResearch bloodCancer Personalized ProfilingDefinity®

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility of sonobiopsy as measured by change in ctDNA level
Measured over Day 1
+1 more outcome measured

Conditions

Glioblastoma
Glioblastoma Multiforme

Explore related trials

Brain NeoplasmGlioblastoma

Where it's being run

1 sites across 1 states
Missouri1

Study leadership

  • Albert Kim, M.D. · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine

Who to contact

Albert Kim, M.D.
[email protected]
314-747-6561
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Must be newly diagnosed with a lesion in the brain with imaging characteristics consistent with glioblastoma multiforme. Scan must have occurred no more than 28 days prior to enrollment.
Lesion must be \> 3 cm in maximal dimension on MRI.
Lesion must be in the supratentorial space within 5 cm of the cortical surface.
Lesion must be gadolinium enhancing.
Low grade tumors and metastatic tumors
Recurrent brain tumors and/or radiation necrosis
Must be planning to undergo surgical resection of the tumor.
Must be at least 18 years old.
Patients with recurrent GBM who are planning to undergo surgical resection or laser ablation of the recurrent tumor. Recurrence must be confirmed on MRI performed no more than 28 days prior to enrollment.

Exclusion

Contraindication to MRI.
Previous cranial surgery.
Previous history of cancer and/or cancer treatments.
Coagulopathy within 14 days of enrollment defined as PT/PTT outside of normal parameters and platelets \< 100,000/mcL.
Physical skull defect of any kind.
Ferrous material in the scalp or skull.
Scalp or skin disease that limits contact with the ultrasound probe.
Enrolled in another clinical trial where intervention is administered prior to surgery.
Known hypersensitivity to polyethylene glycol.
Known unstable cardiopulmonary condition (e.g. acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, serious ventricular arrhythmias).

What this trial measures

  • Feasibility of sonobiopsy as measured by change in ctDNA levelDay 1

    The feasibility of sonobiopsy will be demonstrated by an increase in the amount of ctDNA in the blood samples acquired post than prior sonobiopsy in at least 50% of the patients.

  • Number of matched mutations between the post-sonobiopsy sample and the tumor tissue sampleDay 1

    The agreement of the post-sonobiopsy sample mutation detected in the blood with a variant identified in the tumor tissue will be compared using a kappa statistic.